A New Player in the Development of TRAIL Based Therapies for Hepatocarcinoma Treatment: ATM Kinase
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A New Player in the Development of TRAIL Based Therapies for Hepatocarcinoma Treatment: ATM Kinase
Authors
Keywords
-
Journal
Cancers
Volume 4, Issue 2, Pages 354-378
Publisher
MDPI AG
Online
2012-04-05
DOI
10.3390/cancers4020354
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Enhancement of tumor-TRAIL susceptibility by modulation of autophagy
- (2014) Wen Hou et al. Autophagy
- Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3
- (2012) Kuen-Feng Chen et al. BIOCHEMICAL PHARMACOLOGY
- Guggulsterone sensitizes hepatoma cells to TRAIL-induced apoptosis through the induction of CHOP-dependent DR5: Involvement of ROS-dependent ER-stress
- (2011) Dong-Oh Moon et al. BIOCHEMICAL PHARMACOLOGY
- Role of autophagy in chemoresistance: Regulation of the ATM-mediated DNA-damage signaling pathway through activation of DNA–PKcs and PARP-1
- (2011) Jung-Hoon Yoon et al. BIOCHEMICAL PHARMACOLOGY
- Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents
- (2011) Wenge Wang et al. CANCER BIOLOGY & THERAPY
- ABT-263 sensitizes TRAIL-resistant hepatocarcinoma cells by downregulating the Bcl-2 family of anti-apoptotic protein
- (2011) Guan Wang et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- 5, 7-Dimethoxyflavone sensitizes TRAIL-induced apoptosis through DR5 upregulation in hepatocellular carcinoma cells
- (2011) Jian-Feng Yang et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy
- (2011) P N Kelly et al. CELL DEATH AND DIFFERENTIATION
- ATM protein kinase: the linchpin of cellular defenses to stress
- (2011) Shahzad Bhatti et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- TRAIL and guardian angel of genome integrity: ATM boards TRAIL blazer
- (2011) Ammad Ahmad Farooqi et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- shRNA-mediated silencing of Gli2 gene inhibits proliferation and sensitizes human hepatocellular carcinoma cells towards TRAIL-induced apoptosis
- (2011) Dawei Zhang et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Inflammation meets cancer, with NF-κB as the matchmaker
- (2011) Yinon Ben-Neriah et al. NATURE IMMUNOLOGY
- Capsaicin sensitizes TRAIL-induced apoptosis through Sp1-mediated DR5 up-regulation: Involvement of Ca2+ influx
- (2011) Dong-Oh Moon et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- J7, a methyl jasmonate derivative, enhances TRAIL-mediated apoptosis through up-regulation of reactive oxygen species generation in human hepatoma HepG2 cells
- (2011) Cheol Park et al. TOXICOLOGY IN VITRO
- Targeting the Anti-Apoptotic Protein c-FLIP for Cancer Therapy
- (2011) Ahmad R. Safa et al. Cancers
- Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer
- (2010) T Trarbach et al. BRITISH JOURNAL OF CANCER
- Phase I Trial of Weekly Tigatuzumab, an Agonistic Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5)
- (2010) Andres Forero-Torres et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors
- (2010) T. Doi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Synergistic Effect of Celecoxib on TRAIL-induced Apoptosis in Hepatocellular Carcinoma Cells
- (2010) Guoyue Lu et al. CANCER INVESTIGATION
- DNMT1 and DNMT3b silencing sensitizes human hepatoma cells to TRAIL-mediated apoptosis via up-regulation of TRAIL-R2/DR5 and caspase-8
- (2010) Satoshi Kurita et al. CANCER SCIENCE
- ATM kinase activity modulates cFLIP protein levels: potential interplay between DNA damage signalling and TRAIL-induced apoptosis
- (2010) Venturina Stagni et al. CARCINOGENESIS
- NF-κB and STAT3 – key players in liver inflammation and cancer
- (2010) Guobin He et al. CELL RESEARCH
- Inhibition of casein kinase 2 enhances the death ligand- and natural kiler cell-induced hepatocellular carcinoma cell death
- (2010) H.-R. Kim et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Potent Antitumor Activity in Experimental Hepatocellular Carcinoma by Adenovirus-Mediated Coexpression of TRAIL and shRNA against COX-2
- (2010) Q. Chen et al. CLINICAL CANCER RESEARCH
- A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors
- (2010) R. S. Herbst et al. CLINICAL CANCER RESEARCH
- Expression, Cellular Distribution, and Prognostic Relevance of TRAIL Receptors in Hepatocellular Carcinoma
- (2010) L. Kriegl et al. CLINICAL CANCER RESEARCH
- Sorafenib Overcomes TRAIL Resistance of Hepatocellular Carcinoma Cells through the Inhibition of STAT3
- (2010) K.-F. Chen et al. CLINICAL CANCER RESEARCH
- Proapoptotic DR4 and DR5 signaling in cancer cells: toward clinical translation
- (2010) Annie Yang et al. CURRENT OPINION IN CELL BIOLOGY
- Parthenolide sensitizes hepatocellular carcinoma cells to trail by inducing the expression of death receptors through inhibition of STAT3 activation
- (2010) Daniela Carlisi et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Butein Sensitizes Human Hepatoma Cells to TRAIL-Induced Apoptosis via Extracellular Signal-Regulated Kinase/Sp1-Dependent DR5 Upregulation and NF- B Inactivation
- (2010) D.-O. Moon et al. MOLECULAR CANCER THERAPEUTICS
- β-Ionone Enhances TRAIL-Induced Apoptosis in Hepatocellular Carcinoma Cells through Sp1-Dependent Upregulation of DR5 and Downregulation of NF-κB Activity
- (2010) Mun-Ock Kim et al. MOLECULAR CANCER THERAPEUTICS
- The Synthetic Cannabinoid WIN 55,212-2 Sensitizes Hepatocellular Carcinoma Cells to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)-Induced Apoptosis by Activating p8/CCAAT/Enhancer Binding Protein Homologous Protein (CHOP)/Death Receptor 5 (DR5) Axis
- (2010) O. Pellerito et al. MOLECULAR PHARMACOLOGY
- TRAIL treatment provokes mutations in surviving cells
- (2010) M M Lovric et al. ONCOGENE
- Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors
- (2009) H. A. Wakelee et al. ANNALS OF ONCOLOGY
- Genistein sensitizes human hepatocellular carcinoma cells to TRAIL-mediated apoptosis by enhancing Bid cleavage
- (2009) Cheng-Yun Jin et al. ANTI-CANCER DRUGS
- Inhibition of Ataxia Telangiectasia Mutated Kinase Activity Enhances TRAIL-Mediated Apoptosis in Human Melanoma Cells
- (2009) V. N. Ivanov et al. CANCER RESEARCH
- Peroxiredoxin I contributes to TRAIL resistance through suppression of redox-sensitive caspase activation in human hepatoma cells
- (2009) In-Sung Song et al. CARCINOGENESIS
- Genistein enhances TRAIL-induced apoptosis through inhibition of p38 MAPK signaling in human hepatocellular carcinoma Hep3B cells
- (2009) Cheng-Yun Jin et al. CHEMICO-BIOLOGICAL INTERACTIONS
- TAK1 activates AMPK-dependent cytoprotective autophagy in TRAIL-treated epithelial cells
- (2009) Griselda Herrero-Martín et al. EMBO JOURNAL
- The histone deacetylase inhibitor suberoylanilide hydroxamic acid sensitises human hepatocellular carcinoma cells to TRAIL-induced apoptosis by TRAIL-DISC activation
- (2009) Daniela Carlisi et al. EUROPEAN JOURNAL OF CANCER
- Induction of p53 Renders ATM-Deficient Mice Refractory to Hepatocarcinogenesis
- (2009) Narci Teoh et al. GASTROENTEROLOGY
- The combined status of ATM and p53 link tumor development with therapeutic response
- (2009) H. Jiang et al. GENES & DEVELOPMENT
- CHM-1, a New Vascular Targeting Agent, Induces Apoptosis of Human Umbilical Vein Endothelial Cells via p53-mediated Death Receptor 5 Up-regulation
- (2009) An-Chi Tsai et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Notch1 Signaling Sensitizes Tumor Necrosis Factor-related Apoptosis-inducing Ligand-induced Apoptosis in Human Hepatocellular Carcinoma Cells by Inhibiting Akt/Hdm2-mediated p53 Degradation and Up-regulating p53-dependent DR5 Expression
- (2009) Chunmei Wang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Dysregulation of apoptosis in hepatocellular carcinoma cells
- (2009) Isabel Fabregat WORLD JOURNAL OF GASTROENTEROLOGY
- TRAIL-induced apoptosis of hepatocellular carcinoma cells isaugmented by targeted therapies
- (2009) Bruno Christian Koehler et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Caveolin-1 negatively regulates TRAIL-induced apoptosis in human hepatocarcinoma cells
- (2008) Xiangxuan Zhao et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Glycogen synthase kinase-3 inhibitors augment TRAIL-induced apoptotic death in human hepatoma cells
- (2008) Eléonore Beurel et al. BIOCHEMICAL PHARMACOLOGY
- Transient Inhibition of ATM Kinase Is Sufficient to Enhance Cellular Sensitivity to Ionizing Radiation
- (2008) M. D. Rainey et al. CANCER RESEARCH
- Differential responsiveness of human hepatoma cellsversusnormal hepatocytes to TRAIL in combination with either histone deacetylase inhibitors or conventional cytostatics
- (2008) Johanna Dzieran et al. CANCER SCIENCE
- Hepatitis B virus core protein inhibits TRAIL-induced apoptosis of hepatocytes by blocking DR5 expression
- (2008) J Du et al. CELL DEATH AND DIFFERENTIATION
- TRAIL receptor-targeted therapeutics: Resistance mechanisms and strategies to avoid them
- (2008) A THORBURN et al. DRUG RESISTANCE UPDATES
- Apomab: An agonist monoclonal antibody directed against Death Receptor 5/TRAIL-Receptor 2 for use in the treatment of solid tumors
- (2008) D Ross Camidge EXPERT OPINION ON BIOLOGICAL THERAPY
- JNK inhibition sensitises hepatocellular carcinoma cells but not normal hepatocytes to the TNF-related apoptosis-inducing ligand
- (2008) S R Mucha et al. GUT
- Expression of X-linked inhibitor-of-apoptosis protein in hepatocellular carcinoma promotes metastasis and tumor recurrence
- (2008) Ying-Hong Shi et al. HEPATOLOGY
- Molecular targeted therapies in hepatocellular carcinoma
- (2008) Josep M. Llovet et al. HEPATOLOGY
- Melittin, a Major Component of Bee Venom, Sensitizes Human Hepatocellular Carcinoma Cells to Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-induced Apoptosis by Activating CaMKII-TAK1-JNK/p38 and Inhibiting IκBα Kinase-NFκB
- (2008) Chen Wang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Quercetin sensitizes human hepatoma cells to TRAIL-induced apoptosis via Sp1-mediated DR5 up-regulation and proteasome-mediated c-FLIPSdown-regulation
- (2008) Jin Yeop Kim et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development
- (2008) Anne Grosse-Wilde et al. JOURNAL OF CLINICAL INVESTIGATION
- TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis
- (2008) Niklas Finnberg et al. JOURNAL OF CLINICAL INVESTIGATION
- Death Receptor-Induced Activation of the Chk2- and Histone H2AX-Associated DNA Damage Response Pathways
- (2008) S. Solier et al. MOLECULAR AND CELLULAR BIOLOGY
- Directing cancer cells to self-destruct with pro-apoptotic receptor agonists
- (2008) Avi Ashkenazi NATURE REVIEWS DRUG DISCOVERY
- Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer
- (2008) Martin F. Lavin NATURE REVIEWS MOLECULAR CELL BIOLOGY
- IAP-targeted therapies for cancer
- (2008) E C LaCasse et al. ONCOGENE
- Synergistic antitumor activity of XIAP-shRNA and TRAIL expressed by oncolytic adenoviruses in experimental HCC
- (2007) Qiuwei Pan et al. ACTA ONCOLOGICA
- ATM kinase activity modulates Fas sensitivity through the regulation of FLIP in lymphoid cells
- (2007) V. Stagni et al. BLOOD
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started